Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.40 |
| ▸ | PGR | P06401 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.36 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.36 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148561 | 1.00 | CTDSP1 (0.41) | CTDSP1NR1I2PGRPPARGESR1 | |
| SCHEMBL5500959 | 1.00 | CTDSP1 (0.41) | CTDSP1NR1I2PGRPPARGESR1 | |
| SCHEMBL5150595 | 0.91 | NR1I2 (0.45) | CTDSP1NR1I2PGRPPARGESR1 | |
| SCHEMBL5150599 | 0.91 | NR1I2 (0.45) | CTDSP1NR1I2PGRPPARGESR1 | |
| SCHEMBL18939193 | 0.90 | NR1I2 (0.43) | CTDSP1NR1I2PGRPPARGESR1 | |
| SCHEMBL18939191 | 0.90 | NR1I2 (0.43) | CTDSP1NR1I2PGRPPARGESR1 | |
| SCHEMBL18467327 | 0.89 | NR1I2 (0.48) | CTDSP1NR1I2PGRPPARGESR1 | |
| SCHEMBL15991693 | 0.89 | NR1I2 (0.48) | CTDSP1NR1I2PGRPPARGESR1 | |
| SCHEMBL15991695 | 0.89 | NR1I2 (0.48) | CTDSP1NR1I2PGRPPARGESR1 | |
| SCHEMBL15991697 | 0.89 | NR1I2 (0.48) | CTDSP1NR1I2PGRPPARGESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347362-B1 | PROCESS FOR PREPARING CEFTOLOZANE FROM 7-AMINOCEPHALOSPORANIC ACID (7-ACA) | SANDOZ AG (CH) | 2019-10-23 | — | — | EP | disclosed |
| US-9695196-B2 | Reactions of thiadiazolyl-oximinoacetic acid derivative compounds | MERCK SHARP & DOHME CORP. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170129906-A1 | REACTIONS OF THIADIAZOLYL-OXIMINOACETIC ACID DERIVATIVE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-05-11 | — | — | US | disclosed |
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-7179801-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| EP-1392704-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20040248875-A1 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | CTDSP1 1117/4885NR1I2 603/4885PGR 2604/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | CTDSP1 597/4885NR1I2 385/4885PGR 3749/4885 |
| US-20170129906-A1 | REACTIONS OF THIADIAZOLYL-OXIMINOACETIC ACID DERIVATIVE COMPOUNDS | TST, DCTD, MLYCD | CTDSP1 1165/4885NR1I2 3211/4885PGR 3738/4885 |
| US-20040248875-A1 | Cephem compounds | CEP170, C1S, SLC7A1 | CTDSP1 541/4885NR1I2 716/4885PGR 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.